Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Tőkés T[au]:

Search results

Items: 33

1.

Prognostic and Clinicopathological Correlations of Cell Cycle Marker Expressions before and after the Primary Systemic Therapy of Breast Cancer.

Tőkés T, Tőkés AM, Szentmártoni G, Kiszner G, Mühl D, Molnár BÁ, Kulka J, Krenács T, Dank M.

Pathol Oncol Res. 2019 Aug 24. doi: 10.1007/s12253-019-00726-w. [Epub ahead of print]

PMID:
31446607
2.

Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer.

Tőkés AM, Rusz O, Cserni G, Tóth E, Rubovszky G, Tőkés T, Vízkeleti L, Reiniger L, Kószó R, Kahán Z, Kulka J, Donia M, Vörös A, Szallasi Z.

Acta Oncol. 2019 Jul 4:1-9. doi: 10.1080/0284186X.2019.1633015. [Epub ahead of print]

PMID:
31271119
3.

11Boron Delivery Agents for Boron Proton-capture Enhanced Proton Therapy.

Hideghéty K, Brunner S, Cheesman A, Szabó ER, Polanek R, Margarone D, Tőkés T, Mogyorósi K.

Anticancer Res. 2019 May;39(5):2265-2276. doi: 10.21873/anticanres.13343. Review.

PMID:
31092418
4.

Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations.

Kajáry K, Lengyel Z, Tőkés AM, Kulka J, Dank M, Tőkés T.

Pathol Oncol Res. 2019 Apr 3. doi: 10.1007/s12253-019-00641-0. [Epub ahead of print]

PMID:
30941738
5.

Comparison of different motion correction techniques for dynamic FDG-PET/CT studies in breast cancer patients.

Tőkés T, Dank M, Lengyel Z, Kajáry K.

Q J Nucl Med Mol Imaging. 2019 Feb 21. doi: 10.23736/S1824-4785.19.03114-5. [Epub ahead of print]

PMID:
30792380
6.

A novel vertebrate system for the examination and direct comparison of the relative biological effectiveness for different radiation qualities and sources.

Szabó ER, Reisz Z, Polanek R, Tőkés T, Czifrus S, Pesznyák C, Biró B, Fenyvesi A, Király B, Molnár J, Brunner S, Daroczi B, Varga Z, Hideghéty K.

Int J Radiat Biol. 2018 Nov;94(11):985-995. doi: 10.1080/09553002.2018.1511928. Epub 2018 Oct 17.

PMID:
30332320
7.

Excessive alcohol consumption induces methane production in humans and rats.

Tuboly E, Molnár R, Tőkés T, Turányi RN, Hartmann P, Mészáros AT, Strifler G, Földesi I, Siska A, Szabó A, Mohácsi Á, Szabó G, Boros M.

Sci Rep. 2017 Aug 4;7(1):7329. doi: 10.1038/s41598-017-07637-3.

8.

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients.

Bottai G, Raschioni C, Székely B, Di Tommaso L, Szász AM, Losurdo A, Győrffy B, Ács B, Torrisi R, Karachaliou N, Tőkés T, Caruso M, Kulka J, Roncalli M, Santoro A, Mantovani A, Rosell R, Reis-Filho JS, Santarpia L.

NPJ Breast Cancer. 2016 Nov 2;2:16033. doi: 10.1038/npjbcancer.2016.33. eCollection 2016.

9.

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.

Ács B, Zámbó V, Vízkeleti L, Szász AM, Madaras L, Szentmártoni G, Tőkés T, Molnár BÁ, Molnár IA, Vári-Kakas S, Kulka J, Tőkés AM.

Diagn Pathol. 2017 Feb 21;12(1):20. doi: 10.1186/s13000-017-0608-5.

10.

l-Alpha Glycerylphosphorylcholine as a Potential Radioprotective Agent in Zebrafish Embryo Model.

Szabó ER, Plangár I, Tőkés T, Mán I, Polanek R, Kovács R, Fekete G, Szabó Z, Csenki Z, Baska F, Hideghéty K.

Zebrafish. 2016 Dec;13(6):481-488. Epub 2016 Aug 3.

11.

Defining the design space for freeze-dried orodispersible tablets with meloxicam.

Iurian S, Tomuta I, Bogdan C, Rus L, Tokes T, Barbu-Tudoran L, Achim M, Moldovan M, Leucuta S.

Drug Dev Ind Pharm. 2016 Dec;42(12):1977-1989. Epub 2016 Jun 1.

PMID:
27165764
12.
13.

Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer.

Tőkés T, Tőkés AM, Szentmártoni G, Kiszner G, Madaras L, Kulka J, Krenács T, Dank M.

Virchows Arch. 2016 Jun;468(6):675-86. doi: 10.1007/s00428-016-1925-x. Epub 2016 Mar 30.

PMID:
27026269
14.

Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer.

Tőkés T, Kajáry K, Szentmártoni G, Lengyel Z, Györke T, Torgyík L, Somlai K, Tőkés AM, Kulka J, Dank M.

Breast Cancer. 2017 Jan;24(1):137-146. doi: 10.1007/s12282-016-0685-4. Epub 2016 Mar 15.

PMID:
26979062
15.

The mitochondrial function of the cerebral vasculature in insulin-resistant Zucker obese rats.

Merdzo I, Rutkai I, Tokes T, Sure VN, Katakam PV, Busija DW.

Am J Physiol Heart Circ Physiol. 2016 Apr 1;310(7):H830-8. doi: 10.1152/ajpheart.00964.2015. Epub 2016 Feb 12.

16.

C5a inhibitor protects against ischemia/reperfusion injury in rat small intestine.

Tuboly E, Futakuchi M, Varga G, Érces D, Tőkés T, Mészáros A, Kaszaki J, Suzui M, Imai M, Okada A, Okada N, Boros M, Okada H.

Microbiol Immunol. 2016 Jan;60(1):35-46. doi: 10.1111/1348-0421.12338.

17.

Complexity of Response Evaluation During Primary Systemic Therapy of Breast Cancer: Scoring Systems and Beyond-Preliminary Results.

Tőkés T, Szentmártoni G, Torgyík L, Somlai K, Kulka J, Lengyel Z, Györke T, Dank M.

Anticancer Res. 2015 Sep;35(9):5063-72.

PMID:
26254408
18.

Novel real-time cell analysis platform for the dynamic monitoring of ionizing radiation effects on human tumor cell lines and primary fibroblasts.

Mán I, Szebeni GJ, Plangár I, Szabó ER, Tőkés T, Szabó Z, Nagy Z, Fekete G, Fajka-Boja R, Puskás LG, Hideghéty K, Hackler L Jr.

Mol Med Rep. 2015 Sep;12(3):4610-1619. doi: 10.3892/mmr.2015.4004. Epub 2015 Jun 26.

PMID:
26126392
19.

Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study.

Tőkés T, Szentmártoni G, Torgyík L, Kajáry K, Lengyel Z, Györke T, Molnár BÁ, Tőkés AM, Kulka J, Dank M.

Croat Med J. 2015 Apr;56(2):128-38.

20.

Primary systemic therapy for breast cancer: Does the patient's involvement in decision-making create a new future?

Tőkés T, Torgyík L, Szentmártoni G, Somlai K, Tóth A, Kulka J, Dank M.

Patient Educ Couns. 2015 Jun;98(6):695-703. doi: 10.1016/j.pec.2015.02.012. Epub 2015 Feb 25. Review.

PMID:
25749023
21.

Improvement of small intestinal microcirculation by postconditioning after lower limb ischemia.

Turóczi Z, Fülöp A, Czigány Z, Varga G, Rosero O, Tökés T, Kaszaki J, Lotz G, Harsányi L, Szijártó A.

Microvasc Res. 2015 Mar;98:119-25. doi: 10.1016/j.mvr.2015.02.001. Epub 2015 Feb 7.

PMID:
25665869
22.

Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer.

Kajáry K, Tőkés T, Dank M, Kulka J, Szakáll S Jr, Lengyel Z.

Nucl Med Commun. 2015 Jan;36(1):28-37. doi: 10.1097/MNM.0000000000000217.

PMID:
25299471
23.

Radio-neuroprotective effect of L-alpha-glycerylphosphorylcholine (GPC) in an experimental rat model.

Plangár I, Szabó ER, Tőkés T, Mán I, Brinyiczki K, Fekete G, Németh I, Ghyczy M, Boros M, Hideghéty K.

J Neurooncol. 2014 Sep;119(2):253-61. doi: 10.1007/s11060-014-1489-z. Epub 2014 Jun 1.

PMID:
24880750
24.

Protective effects of L-alpha-glycerylphosphorylcholine on ischaemia-reperfusion-induced inflammatory reactions.

Tőkés T, Tuboly E, Varga G, Major L, Ghyczy M, Kaszaki J, Boros M.

Eur J Nutr. 2015 Feb;54(1):109-18. doi: 10.1007/s00394-014-0691-2. Epub 2014 Mar 28.

PMID:
24682350
25.

[Monoclonal antibody therapy in breast cancer].

Dank M, Tõkés T.

Magy Onkol. 2013 Sep;57(3):157-65. doi: MagyOnkol.2013.57.3.157. Epub 2013 Aug 9. Review. Hungarian.

26.

Peripheral inflammatory activation after hippocampus irradiation in the rat.

Tőkés T, Varga G, Garab D, Nagy Z, Fekete G, Tuboly E, Plangár I, Mán I, Szabó RE, Szabó Z, Volford G, Ghyczy M, Kaszaki J, Boros M, Hideghéty K.

Int J Radiat Biol. 2014 Jan;90(1):1-6. doi: 10.3109/09553002.2013.836617. Epub 2013 Sep 13.

PMID:
23968122
27.

Development of a small-animal focal brain irradiation model to study radiation injury and radiation-injury modifiers.

Hideghéty K, Plangár I, Mán I, Fekete G, Nagy Z, Volford G, Tőkés T, Szabó E, Szabó Z, Brinyiczki K, Mózes P, Németh I.

Int J Radiat Biol. 2013 Aug;89(8):645-55. doi: 10.3109/09553002.2013.784424. Epub 2013 Apr 16.

PMID:
23484794
28.

[The role of FDG-PET-CT in the evaluation of primary systemic therapy in breast cancer: links between metabolic and pathological remission].

Tőkés T, Somlai K, Székely B, Kulka J, Szentmártoni G, Torgyík L, Galgóczy H, Lengyel Z, Györke T, Dank M.

Orv Hetil. 2012 Dec 9;153(49):1958-64. doi: 10.1556/OH.2012.29495. Hungarian.

PMID:
23204302
29.

[Comparative study of novel therapeutic possibilities in animal experimental model of inflammatory bowel disease].

Kovács T, Varga G, Erces D, Tőkés T, Tiszlavicz L, Ghyczy M, Vécsei L, Boros M, Kaszaki J.

Magy Seb. 2012 Aug;65(4):191-7. doi: 10.1556/MaSeb.65.2012.4.4. Hungarian.

PMID:
22940387
30.

N-methyl-D-aspartate receptor antagonist therapy suppresses colon motility and inflammatory activation six days after the onset of experimental colitis in rats.

Érces D, Varga G, Fazekas B, Kovács T, Tőkés T, Tiszlavicz L, Fülöp F, Vécsei L, Boros M, Kaszaki J.

Eur J Pharmacol. 2012 Sep 15;691(1-3):225-34. doi: 10.1016/j.ejphar.2012.06.044. Epub 2012 Jul 14.

PMID:
22796676
31.

Dietary phosphatidylcholine supplementation attenuates inflammatory mucosal damage in a rat model of experimental colitis.

Kovács T, Varga G, Erces D, Tőkés T, Tiszlavicz L, Ghyczy M, Boros M, Kaszaki J.

Shock. 2012 Aug;38(2):177-85. doi: 10.1097/SHK.0b013e31825d1ed0.

PMID:
22576006
32.

The anti-inflammatory effects of methane.

Boros M, Ghyczy M, Érces D, Varga G, Tőkés T, Kupai K, Torday C, Kaszaki J.

Crit Care Med. 2012 Apr;40(4):1269-78. doi: 10.1097/CCM.0b013e31823dae05.

PMID:
22336723
33.

Protective effects of a phosphatidylcholine-enriched diet in lipopolysaccharide-induced experimental neuroinflammation in the rat.

Tokés T, Eros G, Bebes A, Hartmann P, Várszegi S, Varga G, Kaszaki J, Gulya K, Ghyczy M, Boros M.

Shock. 2011 Nov;36(5):458-65. doi: 10.1097/SHK.0b013e31822f36b0.

PMID:
21937953

Supplemental Content

Support Center